Molecular classification of soft tissue sarcomas and its clinical applications

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 4, 2010, Pages 416-429

  Jain, Shilpa ^a   Xu, Ruliang ^a   Prieto, Victor G ^b   Lee, Peng ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

molecular classification; Molecular genetics; Sarcomas; Soft tissue tumors; Specific genetic translocation

Indexed keywords

CLASSIFICATION; GENETICS; HUMAN; REVIEW; SARCOMA; SOFT TISSUE TUMOR;

HUMANS; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 77955880551     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Riggi N, Cironi L, Suva ML and Stamenkovic I. Sarcomas: Genetics, signalling, and cellular origins. Part 1: The fellowship of TET. J Pathol 2007; 213: 4-20.
2. Olsen SH, Thomas DG and Lucas DR. Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod Pathol 2006; 19: 659-668.
3. de Alava E and Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000; 18: 204-213.
4. Kilpatrick SE, Bergman S, Pettenati MJ and Gulley ML. The usefulness of cytogenetic analysis in fine needle aspirates for the histologic subtyping of sarcomas. Mod Pathol 2006; 19: 815-819.
5. Lin PP, Brody RI, Hamelin AC, Bradner JE, Healey JH and Ladanyi M. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res 1999; 59: 1428-1432.
6. Vermeulen J, Ballet S, Oberlin O, Peter M, Pierron G, Longavenne E, Laurence V, Kanold J, Chastagner P, Lejars O, Blay JY, Marec-Berard P, Michon J, Delattre O and Schleiermacher G. Incidence and prognostic value of tumour cells detected by RT-PCR in peripheral blood stem cell collections from patients with Ewing tumour. Br J Cancer 2006; 95: 1326-1333.
7. Hameed M. Small round cell tumors of bone. Arch Pathol Lab Med 2007; 131: 192-204.
8. Ladanyi M and Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res 1994; 54: 2837-2840.
9. Murphy AJ, Bishop K, Pereira C, Chilton-MacNeill S, Ho M, Zielenska M and Thorner PS. A new molecular variant of desmoplastic small round cell tumor: significance of WT1 immunostaining in this entity. Hum Pathol 2008; 39: 1763-1770.
10. Nishio J, Iwasaki H, Ishiguro M, Fukuda T, Chuman H, Kaneko Y and Kikuchi M. Intraabdominal small round cell tumour with EWSWT1 fusion transcript in an elderly patient. Histopathology 2003; 42: 410-412.
11. Hisaoka M, Ishida T, Kuo TT, Matsuyama A, Imamura T, Nishida K, Kuroda H, Inayama Y, Oshiro H, Kobayashi H, Nakajima T, Fukuda T, Ae K and Hashimoto H. Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases. Am J Surg Pathol 2008; 32: 452-460.
12. Stenman G, Andersson H, Mandahl N, Meis-Kindblom JM and Kindblom LG. Translocation t (9;22)(q22;q12) is a primary cytogenetic abnormality in extraskeletal myxoid chondrosarcoma. Int J Cancer 1995; 62: 398-402.
13. Clark J, Benjamin H, Gill S, Sidhar S, Goodwin G, Crew J, Gusterson BA, Shipley J and Cooper CS. Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma. Oncogene 1996; 12: 229-235.
14. Sjogren H, Meis-Kindblom JM, Orndal C, Bergh P, Ptaszynski K, Aman P, Kindblom LG and Stenman G. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcomacytogenetic, molecular genetic, and cDNA microarray analyses. Am J Pathol 2003; 162: 781-792.
15. Hisaoka M, Ishida T, Imamura T and Hashimoto H. TFG is a novel fusion partner of NOR1 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer 2004; 40: 325-328.
16. Antonescu CR, Argani P, Erlandson RA, Healey JH, Ladanyi M and Huvos AG. Skeletal and extraskeletal myxoid chondrosarcoma: a comparative clinicopathologic, ultrastructural, and molecular study. Cancer 1998; 83: 1504-1521.
17. Matsuyama A, Hisaoka M, Shimajiri S and Hashimoto H. DNA-based polymerase chain reaction for detecting FUS-CREB3L2 in low-grade fibromyxoid sarcoma using formalin-fixed, paraffinembedded tissue specimens. Diagn Mol Pathol 2008; 17: 237-240.
18. Rubin BP, Chen CJ, Morgan TW, Xiao S, Grier HE, Kozakewich HP, Perez-Atayde AR and Fletcher JA. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 1998; 153: 1451-1458.
19. Knezevich SR, McFadden DE, Tao W, Lim JF and Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998; 18: 184-187.
20. Iwasaki H, Nabeshima K, Nishio J, Jimi S, Aoki M, Koga K, Hamasaki M, Hayashi H and Mogi A. Pathology of soft-tissue tumors: daily diagnosis, molecular cytogenetics and experimental approach. Pathol Int 2009; 59: 501-521.
21. Oda Y, Sakamoto A, Saito T, Kinukawa N, Iwamoto Y and Tsuneyoshi M. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol 2000; 31: 185-192.
22. Kanemitsu S, Hisaoka M, Shimajiri S, Matsuyama A and Hashimoto H. Molecular detection of SS18-SSX fusion gene transcripts by cRNA in situ hybridization in synovial sarcoma using formalin-fixed, paraffin-embedded tumor tissue specimens. Diagn Mol Pathol 2007; 16: 9-17.
23. Skytting B, Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlen M and Larsson O. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst 1999; 91: 974-975.
24. Nishio J, Iwasaki H, Althof PA, Naumann S, Ishiguro M, Haraoka S, Iwashita A, Iwasaki A, Kaku Y, Kaneko Y, Kikuchi M and Bridge JA. Identification of a ring chromosome with spectral karyotyping in a pleural synovial sarcoma. Cancer Genet Cytogenet 2005; 160: 174-178.
25. Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Fujita C, Isayama T, Naito M, Oda Y, Kaneko Y and Kikuchi M. Establishment of a new human synovial sarcoma cell line, FU-SY-1, that expresses c-Met receptor and its ligand hepatocyte growth factor. Int J Oncol 2002; 21: 17-23.
26. Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Isayama T, Naito M, Kaneko Y, Kamada N and Kikuchi M. Synovial sarcoma with a secondary chromosome change der(22)t(17;22)(q12;q12). Cancer Genet Cytogenet 2002; 137: 23-28.
27. Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Isayama T, Naito M and Kikuchi M. Identification of syt-ssx fusion transcripts in both epithelial and spindle cell components of biphasic synovial sarcoma in small tissue samples isolated by membrane-based laser microdissection. Virchows Arch 2001; 439: 152-157.
28. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JS, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B and Larsson O. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002; 62: 135-140.
29. Hill DA, Riedley SE, Patel AR, Shurtleff SA, Hyer J, Cain AM, Billups CA, Downing JR and Pappo AS. Real-time polymerase chain reaction as an aid for the detection of SYT-SSX1 and SYT-SSX2 transcripts in fresh and archival pediatric synovial sarcoma specimens: report of 25 cases from St. Jude Children's Research Hospital. Pediatr Dev Pathol 2003; 6: 24-34.
30. Jagdis A, Rubin BP, Tubbs RR, Pacheco M and Nielsen TO. Prospective Evaluation of TLE1 as a Diagnostic Immunohistochemical Marker in Synovial Sarcoma. Am J Surg Pathol 2009; 33 (12):1743-51.
31. Simon MP, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre JM, Terrier-Lacombe MJ, Mandahl N, Craver RD, Blin N, Sozzi G, Turc-Carel C, O'Brien KP, Kedra D, Fransson I, Guilbaud C and Dumanski JP. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 1997; 15: 95-98.
32. McArthur GA. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Curr Opin Oncol 2006; 18: 341-346.
33. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN and Crist WM. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003; 21: 78-84.
34. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ and Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006; 66: 6936-6946.
35. Mehra S, de la Roza G, Tull J, Shrimpton A, Valente A and Zhang S. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffinembedded alveolar rhabdomyosarcomas and its clinicopathologic correlation. Diagn Mol Pathol 2008; 17: 14-20.
36. Matsumura T, Yamaguchi T, Seki K, Shimoda T, Wada T, Yamashita T and Hasegawa T. Advantage of FISH analysis using FKHR probes for an adjunct to diagnosis of rhabdomyosarcomas. Virchows Arch 2008; 452: 251-258.
37. Miettinen M and Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-1478.
38. Morgenstern DA, Gibson S, Brown T, Sebire NJ and Anderson J. Clinical and pathological features of paediatric malignant rhabdoid tumours. Pediatr Blood Cancer 2010; 54: 29-34.
39. Flucke U, Slootweg PJ, Mentzel T, Pauwels P and Hulsebos TJ. Re: Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor: Direct evidence of mutational inactivation of SMARCB1/INI1 in epithelioid sarcoma. Hum Pathol 2009; 40: 1361-1362; author reply 1362-1364.
40. Guillou L and Aurias A. Soft tissue sarcomas with complex genomic profiles. Virchows Arch 2009
41. Taylor BS, Barretina J, Socci ND, Decarolis P, Ladanyi M, Meyerson M, Singer S and Sander C. Functional copy-number alterations in cancer. PLoS One 2008; 3: e3179.
42. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, O'Connor R, Maki R, Viale A, Sander C, Schwartz GK and Antonescu CR. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007; 67: 6626-6636.
43. Mita MM and Tolcher AW. The role of mTOR inhibitors for treatment of sarcomas. Curr Oncol Rep 2007; 9: 316-322.
44. Bridge RS, Jr., Bridge JA, Neff JR, Naumann S, Althof P and Bruch LA. Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. J Clin Pathol 2004; 57: 1172-1178.
45. Karube K, Nabeshima K, Ishiguro M, Harada M and Iwasaki H. cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours. J Clin Pathol 2006; 59: 160-165.